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Abstract
A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube
and other epithelia of the upper genital tract; these epithelia may incur damage and
neoplastic transformation after sexually transmitted infections (STI) and pelvic inflam-
matory disease. We investigated the hypothesis that past STI infection, particularly
Chlamydia trachomatis, is associated with higher EOC risk in a nested case-control
study within the European Prospective Investigation into Cancer and Nutrition (EPIC)
cohort including 791 cases and 1669 matched controls. Serum antibodies against
C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV-2) and
human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent
bead-based serology. Conditional logistic regression was used to estimate relative
risks (RR) and 95% confidence intervals (CI) comparing women with positive
vs. negative serology. A total of 40% of the study population was seropositive to at
least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated
with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95%
CI = 1.22-4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60-1)
was associated with higher risk of EOC overall (1.36 [1.13-1.64]) and with the serous
subtype (1.44 [1.12-1.85]). None of the other evaluated STIs were associated with
EOC risk overall; however, HSV-2 was associated with higher risk of endometrioid
EOC (2.35 [1.24-4.43]). The findings of our study suggest a potential role of
C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV-2 might
promote the development of endometrioid disease.
K E YWORD S
Chlamydia trachomatis, herpes simplex virus, human papillomavirus, Mycoplasma genitalium,
ovarian cancer
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1 | INTRODUCTION
Epithelial ovarian cancer (EOC) is a heterogeneous disease, with dis-
tinct histologic subtypes hypothesized to arise via different pathways
of carcinogenesis.1 The low-grade serous, endometrioid and clear cell
histotypes have generally accepted origins and/or precursor lesions,2,3
and are suggested to be more strongly associated with well-known
EOC risk factors (eg, oral contraceptive [OC] use, parity, number of
life-time ovulations, tubal ligation, hysterectomy and endometriosis),
while risk factors for high-grade serous ovarian cancer (HGSC), the
most common and lethal subtype, are less well defined and risk factor
associations are generally weaker for HGSC than for other subtypes.4
Evidence is accumulating that the majority of ovarian cancers originate in
non-ovarian epithelial tissue, for example, the distal fallopian tubes
(HGSC)1,5 or ectopic endometrial tissue (endometrioid/clear cell).
Given the likely extra-ovarian origin of a proportion of EOCs,
exposures associated with tubal pathologies are of increasing interest
with respect to EOC risk. Sexually transmitted infections (STIs) are
associated with a range of gynecologic sequelae including pelvic
inflammatory disease (PID),6,7 PID has been associated with EOC
risk,8,9 though data to date suggest strongest associations with bor-
derline tumors.10 Chlamydia trachomatis and Mycoplasma genitalium
are two sexually transmitted bacterial causes of PID. C. trachomatis
infects the secretory cells of the fallopian tubes in experimental ani-
mal models,11,12 and may promote tumorigenesis by accelerating cell
proliferation, inhibiting cell apoptosis (eg, via chlamydial heat shock
protein 60 [cHSP60] production), promoting host DNA damage, and
inducing chronic inflammation.13 M. genitalium has been shown to
induce chromosomal aberrations and polysomy in benign human pros-
tate cells, and may promote anchorage-independent growth, allowing
cells to detach from the surrounding extracellular matrix and metasta-
size, indicating possible pro-carcinogenic properties.14 Herpes simplex
virus type 2 (HSV-2), a mostly sexually transmitted virus, has been
associated with higher risk of cervical cancer.15 Finally, sexually trans-
mitted human papillomavirus (HPV) has a well-characterized role in
carcinogenesis. HPV infection has its greatest impact in the transfor-
mation zone of the uterine cervix but is also implicated in the develop-
ment of anorectal carcinomas originating in, or close to, the anorectal
squamocolumnar epithelial junction.16 Similarly, the distal end of the
fallopian tubes harbors the potentially vulnerable junction of the
fallopian tubal epithelium and the peritoneal mesothelium.17
Epidemiologic data on STIs and EOC risk are limited and the
results divergent,18-25 and few studies are prospective.18,22,25,26 The
largest and most recent prospective study (n = 337 cases) observed a
twofold higher risk of EOC among women seropositive to chlamydial
Pgp3 antibodies,25 with similar associations between relatively high
circulating antibodies in another recent prospective study18; no asso-
ciations were observed for M. genitalium, the investigated HPV types
(L1 proteins of types 16, 18 and 45), or HSV-2.
Based on experimental and epidemiologic data we hypothesized
that STIs, and C. trachomatis in particular, may play a role in the devel-
opment of EOC. Given the few prospective studies to date, and no
studies by EOC histotype beyond serous vs nonserous disease, the
aim of our study was to assess the association between STI serostatus,
analyzed in prospectively collected blood samples, and EOC risk, overall
and by histologic subtype, in a case-control study nested in the
European Prospective Investigation into Cancer and Nutrition (EPIC)
cohort.
2 | MATERIALS AND METHODS
2.1 | Study population: The EPIC cohort
EPIC is an ongoing prospective cohort including 521 330 participants
(367 903 women) selected from the general population generally aged
25-70 years, and enrolled from 1992 to 2000 in 23 centers across
10 European countries: Denmark, France, Germany, Greece, Italy, the
Netherlands, Norway, Spain, Sweden, and the United Kingdom. Study
design, population and data collection have been described previously
in detail.27 Briefly, information on lifestyle, diet, reproductive and
anthropometric factors was collected at baseline. A total of 226 673
women provided a blood sample at recruitment. Participants provided
written informed consent at baseline and the Ethical Committee of
IARC and the University of Heidelberg approved our study.
2.2 | Nested case-control study participant
selection
Study design and case and control selection of this nested case-
control study have been described previously.28 Briefly, cases of epi-
thelial ovarian, fallopian tube and primary peritoneal cancer were
identified through linkages with cancer registries, health insurance
records, and direct contact with cohort members. Data on histologic
subtype and tumor grade were obtained from pathology reports and
cancer registries.
Up to four controls per case were randomly selected using inci-
dence density sampling among all women from the cohort having a
What's new?
Sexually transmitted infections (STI) have been linked with
pelvic inflammatory disease but their association with ovar-
ian cancer remains unclear. In this large prospective study,
serum antibodies against Chlamydia trachomatis were associ-
ated with higher epithelial ovarian cancer risk, though some
associations were limited to select histotypes. Herpes sim-
plex virus type 2 infection was associated with endometrioid
ovarian cancer, a rarer ovarian cancer subtype. These find-
ings underscore that STIs may be important in the etiology
of ovarian cancer and may represent a target for primary
prevention.
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blood sample, with no reported oophorectomy, and alive and free of
cancer at the time of diagnosis of the index case. Cases and controls
were matched on study recruitment center, age at blood donation,
time of the day of blood collection, fasting status, exogenous hor-
mone use at blood donation as well as menstrual cycle phase for
premenopausal women. Further details are provided in the Supple-
mental Methods. A total of 791 cases and 1669 controls were
included in the study (85 cases with 1 control; 606 cases with 2 con-
trols, 8 cases with 3 controls and 82 cases with 4 controls).
2.3 | Laboratory assays
Prediagnosis levels of antibodies to C. trachomatis, M. genitalium,
HSV-2 and HPV were measured using multiplex fluorescent bead-
based serology assays and quantified as median fluorescence inten-
sity (MFI) levels.29 Samples from cases and controls were analyzed
within the same analytical batch and laboratory personnel were
blinded to case-control status. C. trachomatis infection history was
assessed measuring antibodies to Pgp318 and cHSP60-1, plus
MOMP-D, MOMP-A, MOMP-L2, TARP-F2 and TARP-F1 from
serovar D.30 MOMPs representing all three biovars were included
given the high cross-reactivity between MOMP serovars, and the
low prevalence of trachoma (serovar A-C) in Western European
countries. Antibodies to Pgp3, a chlamydia plasmid-encoded protein,
sometimes referred to as the “gold standard” marker of current or
previous infection,18,31,32 as well as antibodies to cHSP60-1, pro-
duced with persistent C. trachomatis infection,33 were the primary
C. trachomatis antibodies of interest. The Pgp3 antibody was positive
in 79.5% of women reporting C. trachomatis infection in a recent
study,31 and cHSP60-1 antibodies have previously been linked to
tubal damage.33 History of M. genitalium was assessed using MgPa
N-Terminus, and rMgPa antibodies.18 HSV-2 antibodies to 2mgG
unique, specific for HSV-2,34 were assessed. HPV infection was
determined using antibodies to types 16, 18 and 45 oncoproteins E6
and E7 and the major capsid protein L1.29 An STI was defined as
seropositive according to cut-off values and rules summarized in
Table S1.
2.4 | Statistical analyses
Conditional logistic regression was used to calculate odds ratios, as esti-
mates of relative risks (RRs), and 95% confidence intervals (95% CIs)
comparing participants seropositive to those seronegative for the individ-
ual infections using the laboratory cut-off levels. Further, a recent study
observed significant associations between C. trachomatis and EOC in one
population using the laboratory cut-off, but in another population only
after applying a higher cut-off level to define C. trachomatis seropositivity
using the Pgp3 antibody.18 Therefore, we also evaluated associations
between the individual C. trachomatis antibodies and EOC risk comparing
“low positive” (laboratory cut-off < MFIindividual < median in positive
women) and “high positive” (MFIindividual ≥ median in positive women), to
seronegative. History of infection with different STIs could potentially
lead to worse tissue damage, and a tendency toward higher risk of EOC
with antibodies to C. trachomatis plus a second infection was found in
one study.25 Thus, infection with C. trachomatis plus any other infection
(M. genitalium, HSV-2, HPV), relative to women negative to all infections,
was investigated. The following were evaluated as potential con-
founders/covariates: ever menopausal hormone therapy (MHT) use
(never, ever), number of full-term pregnancies (FTP; continuous), duration
of OC use (continuous) and smoking status (never, former, current; fur-
ther evaluated as never, former quit 20+ years, former quit 11-20 years,
former quit ≤10 years, current occasional, current 1-15 cigarettes/day,
current 16-25 cigarettes/day, current 26 cigarettes/day). Final multivari-
able models include duration of OC use and number of FTPs. Missing
values (OC duration, 3%; number FTPs, 10.6%) were imputed to the
most frequently observed value for that variable (OC use = never,
FTP = 2); results were unchanged when restricted to women with data
on OC use and parity. RRs changed <10% after including the remaining
variables.
We investigated STIs and EOC overall, by tumor histology
(serous, mucinous, endometrioid, clear cell and NOS), and for HGSC
disease (tumor grades 2 or 3). Heterogeneity in the associations
between the STIs and EOC risk by disease subtype was assessed com-
paring models assuming the same association across subtypes to a
model assuming different associations across subtypes using the likeli-
hood ratio test.35 We conducted a sensitivity analysis restricted to
parous women. Associations between STIs and EOC risk were evalu-
ated by age at blood donation (<60, ≥60 years), lag time between
blood donation and diagnosis (<5, ≥5 years), OC use (ever, never),
menopausal status at blood collection (premenopausal, perimeno-
pausal and postmenopausal); the Wald test was used to assess het-
erogeneity in associations.
Statistical analyses were conducted using SAS software, version
9.3 (SAS Institute, Cary, NC). P values are two-sided and P < .05 was
considered statistically significant.
3 | RESULTS
Median age at blood collection was 56.5 years (range = 29.9-80.7)
and the majority of cases and controls were postmenopausal at blood
collection (cases, 69.1%; controls, 69.6%) and reported at least one
full-term pregnancy (cases, 83.1%; controls, 88.8%; Table 1). Cases
were diagnosed at median age 62.9 years (range = 30.6-86.5), a
median of 6.3 years (range = 0.04-16.0) after blood collection
(Table 2). The majority of cases were of serous histology (54.7%)
followed by “not otherwise specified” (16.7%), endometrioid (11.8%),
mucinous (7.3%) and clear cell (4.7%). Of the 464 cases with grade
data (59% of all cases, 66% of serous cases), 90.5% had moderately or
poorly differentiated tumors. A total of 40% of the study population
(39.5% of controls; 41.0% of cases) was seropositive for at least one
of the investigated STIs. Seroprevalence varied by study country, with
the highest prevalence of antibodies to the evaluated STIs generally
observed in the Nordic countries (eg, ≥42.3% positive for
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C. trachomatis in Sweden, Denmark and Norway vs 15.1% positive in
Spain; Table S2).
Seropositivity to C. trachomatis Pgp3 antibodies was not associated
with EOC risk overall (Table 3). Suggestive heterogeneity by histologic
subtype was observed (P = .07 using lab cutoff; P = .01 using median
MFI in seropositive cutoff). Seropositivity to Pgp3 was associated with
a 2.3-fold higher risk of mucinous EOC (RR = 2.30 [95%CI = 1.22-4.32]);
this association was robust to adjustment for smoking (RR = 2.49
[1.29-4.79]) (result not tabled). No significant associations were
observed for other histotypes and no clear patterns emerged in ana-
lyses evaluating “high positive” (above the median among women
seropositive) and “low positive” (below the median among women sero-
positive) vs seronegative. Women seropositive for the cHSP60-1 anti-
body had 36% higher risk of EOC overall (1.36 [1.13-1.64]), and 44%
higher risk of serous disease (1.44 [1.12-1.85]), relative to seronegative
women; as with the Pgp3 antibodies, there was no pattern in analyses
by high and low seropositive vs seronegative.
We observed associations between the other investigated
C. trachomatis antibodies and EOC risk. Positive MOMP-A serology
was significantly associated with higher risk of overall EOC using
the laboratory cut-off (1.25 [1.04-1.50]), and “high positive” serol-
ogy for MOMP-A and MOMP-D were associated with higher risk
of serous EOC (eg, MOMP-D, 1.44 [1.07-1.92]; Table S3). Rela-
tively high levels of TARP-F1 antibodies were significantly associ-
ated with mucinous EOC (2.29 [1.09-4.78]). Distributions of cases
and controls by seropositivity using the laboratory cut-off as well
as positives above and below median antibody level are provided in
Table S4.
M. genitalium, HSV-2 and HPV16 E6, or HPV18 E6 + E7, or
HPV45 E6 + E7 were not associated with EOC risk, except a positive
TABLE 1 Baseline characteristics of EOC cases and matched
controls: EPIC ovarian cancer nested case-control study
Cases (n = 791) Controls (n = 1669)
Age at blood donation
(years)a
56.5 (29.9, 80.7) 56.5 (30.1, 79.3)
Age at menopause
(years)b
50.0 (32.0, 63.0) 50.0 (30.0, 63.0)
Menopausal statusa
Premenopausal 132 (16.7) 280 (16.8)
Perimenopausal 112 (14.2) 227 (13.6)
Postmenopausal 547 (69.1) 1162 (69.6)
Age at menarche (years)b 13.0 (9.0, 20.0) 13.0 (8.0, 20.0)
Age at first delivery
(years)b
24.0 (16.0, 40.0) 24.0 (14.0, 45.0)
Ever full term pregnancyb 604 (83.1) 1358 (88.8)
Number of full-term birthsb
None 123 (17.3) 172 (11.6)
1 113 (15.9) 247 (16.6)
2 288 (40.5) 632 (42.5)
3 116 (16.3) 284 (19.1)
4+ 72 (10.1) 151 (10.2)
Ever OC useb 331 (43.7) 812 (50.7)
Duration of OC use (years)b 5.00 (1.0, 25.0) 5.00 (1.0, 25.0)
Ever MHT useb 229 (32.0) 488 (32.6)
Duration of MHT use
(years)b
4.0 (0.1, 27.0) 3.0 (0.1, 20.0)
BMI (kg/m2) 25.2 (17.2, 45.4) 25.0 (15.5, 50.6)
Smokingb
Never 421 (54.2) 932 (56.9)
Former 181 (23.3) 377 (23.0)
Current 174 (22.4) 329 (20.1)
Note: Values are shown as median (range) or number (percentage).
aMatching factor.
bNumber of missing values (cases, controls): age at menopause among
postmenopausal women (101, 208), age at menarche (39, 82), age at first
delivery (4, 4), ever full-term pregnancy (64, 139), number of full-term
pregnancies (79, 183), OC use (33, 68), duration of OC use (20, 55), MHT
use (75, 170), duration of MHT use (33, 61) and smoking (15, 31).
Abbreviations: BMI, body mass index; EOC, epithelial ovarian cancer;
EPIC, European Prospective Investigation into Cancer and Nutrition; MHT,
menopausal hormone therapy; OC, oral contraceptive.
TABLE 2 Characteristics of EOC cases: EPIC ovarian cancer
nested case-control study
EOC cases (n = 791)











Distant metastatic 458 (65.9)
Gradec
Well differentiated 44 (9.5)
Moderately differentiated 162 (34.9)
Poorly or undifferentiated 258 (55.6)
Time between blood collection
and EOC diagnosis (years)
6.3 (0.04, 16.0)
Time between blood collection
and EOC diagnosis
<5 years 304 (38.4)
≥5 years 487 (61.6)
Note: Values are shown as median (range) or number (percentage).
an = 268 high-grade serous (data on grade available for 66% [n = 284] of
serous cases).
bLocal: stage I, regional: stage II and IIIa, distant metastatic: stage >IIIb.
cNumber of missing cases: Stage 96, grade 327.
Abbreviations: EOC, epithelial ovarian cancer; EPIC, European Prospective
Investigation into Cancer and Nutrition; NOS, not otherwise specified.
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TABLE 3 Seropositivity to Chlamydia trachomatis and EOC risk overall and by histological subtypes; EPIC ovarian cancer nested case-control
study
C. trachomatis (Pgp3) C. trachomatis (cHSP60-1)
Controls n (%) Cases n (%) RRa (95% CI) Controls n (%) Cases n (%) RRa (95% CI)
EOC
Negative 1176 (70.5) 547 (69.2) ref 1426 (85.4) 647 (81.8) ref
+, lab cut-off 493 (29.5) 244 (30.8) 1.05 (0.89-1.24) 243 (14.6) 144 (18.2) 1.36 (1.13-1.64)
+, MFI < medianb 245 (14.7) 123 (15.5) 1.05 (0.85-1.29) 124 (7.4) 69 (8.7) 1.29 (1.00-1.66)
+, MFI ≥ medianb 248 (14.9) 121 (15.3) 1.05 (0.85-1.30) 119 (7.1) 75 (9.5) 1.43 (1.11-1.85)
Serous
Negative 616 (67.8) 302 (69.7) ref 772 (84.9) 348 (80.4) ref
+, lab cut-off 293 (32.2) 131 (30.3) 0.88 (0.71-1.09) 137 (15.1) 85 (19.6) 1.44 (1.12-1.85)
+, MFI < medianb 158 (17.4) 63 (14.5) 0.77 (0.58-1.02) 73 (8.0) 38 (8.8) 1.19 (0.85-1.67)
+, MFI ≥ medianb 135 (14.9) 68 (15.7) 1.02 (0.77-1.35) 64 (7.0) 47 (10.9) 1.71 (1.22-2.40)
High-grade serousc
Negative 404 (69.8) 197 (73.5) ref 482 (83.2) 223 (83.2) ref
+, lab cut-off 175 (30.2) 71 (26.5) 0.82 (0.63-1.08) 97 (16.8) 45 (16.8) 1.01 (0.73-1.40)
+, MFI < medianb 90 (15.5) 37 (13.8) 0.82 (0.57, 1.19) 54 (9.3) 16 (6.0) 0.66 (0.40-1.07)
+, MFI ≥ medianb 85 (14.7) 34 (12.7) 0.83 (0.57, 1.20) 43 (7.4) 29 (10.8) 1.45 (0.96-2.19)
Mucinous
Negative 93 (73.8) 32 (55.2) ref 110 (87.3) 47 (81.0) ref
+, lab cut-off 33 (26.2) 26 (44.8) 2.30 (1.22-4.32) 16 (12.7) 11 (19.0) 1.83 (0.91-3.65)
+, MFI < medianb 13 (10.3) 11 (19.0) 2.20 (0.97-5.00) 6 (4.8) 4 (6.9) 1.87 (0.66-5.30)
+, MFI ≥ medianb 20 (15.9) 15 (25.9) 2.36 (1.17-4.75) 10 (7.9) 7 (12.1) 1.80 (0.75-4.31)
Endometrioid
Negative 135 (68.2) 62 (66.7) ref 162 (81.8) 75 (80.6) ref
+, lab cut-off 63 (31.8) 31 (33.3) 1.04 (0.66-1.64) 36 (18.2) 18 (19.4) 1.11 (0.66-1.89)
+, MFI < medianb 24 (12.1) 16 (17.2) 1.50 (0.82-2.76) 18 (9.1) 10 (10.8) 1.32 (0.66-2.62)
+, MFI ≥ medianb 39 (19.7) 15 (16.1) 0.78 (0.44-1.41) 18 (9.1) 8 (8.6) 0.93 (0.46-1.88)
Clear cell
Negative 49 (69.0) 28 (75.7) ref 60 (84.5) 34 (91.9) ref
+, lab cut-off 22 (31.0) 9 (24.3) 0.70 (0.32-1.58) 11 (15.5) 3 (8.1) 0.57 (0.16-2.00)
+, MFI < medianb 12 (16.9) 9 (24.3) 1.75 (0.74-4.15) 5 (7.0) 3 (8.1) 1.59 (0.50-5.08)
+, MFI ≥ medianb 10 (14.1) 0 —d 6 (8.5) 0 (0) —d
NOS
Negative 219 (78.5) 93 (70.5) ref 247 (88.5) 110 (83.3) ref
+, lab cut-off 60 (21.5) 39 (29.5) 1.62 (1.06-2.48) 32 (11.5) 22 (16.7) 1.56 (0.96-2.52)
+, MFI < medianb 26 (9.3) 18 (13.6) 1.66 (0.99-2.80) 15 (5.4) 11 (8.3) 1.85 (0.94-3.66)
+, MFI ≥ medianb 34 (12.2) 21 (15.9) 1.58 (0.92-2.72) 17 (6.1) 11 (8.3) 1.35 (0.70-2.60)
Phet by subtype (lab cut-off) .07 .68
Phet by subtype (MFI </≥ median) .01 .36
aRRs estimated from ORs from a conditional logistic regression model; Cases and controls were matched on study recruitment center, age at blood dona-
tion (±6 months), time of the day of blood collection (±1 hour), fasting status (<3, 3-6, >6 hours); exogenous hormone use at blood donation (no/yes) as well
as menstrual cycle phase for premenopausal women (“early follicular” (days 0-7 of the cycle), “late follicular” (days 8-11), “periovulatory” (days 12-16), “mid-
luteal” (days 20-24), “other luteal” (days 17-19 or days 25-40), or missing). Adjusted for number of full term pregnancies and duration of use of oral contra-
ceptives (years); results for mucinous disease robust to additional adjustment for smoking.
b+, MFI < median indicates positive serology using lab cut-off, and MFI value below median among women seropositive according to lab cut-off (“low positive”);
+, MFI ≥median indicates positive serology using lab cutoff, and MFI value above median among women seropositive according to lab cut-off (“high positive”).
cData on grade available for 66% of serous cases.
dNot estimable or not reliable.
Abbreviations: CI, confidence interval; EOC, epithelial ovarian cancer; EPIC, European Prospective Investigation into Cancer and Nutrition; NOS, not other-
wise specified; Phet, heterogeneity by subtype assessed with the likelihood ratio test; RR, relative risk.
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association between HSV-2 and endometrioid EOC (2.35 [1.24-4.43];
Phet by histotype = 0.08; Table 4). No associations were observed for
the HPV-related markers stated above; results were similar when the
L1 antibodies were evaluated (Table 4, footnote). Seropositivity to
C. trachomatis plus a second STI was not associated with EOC risk in
any subgroup (data not shown).
3.1.1. | Sensitivity and subgroup analyses
Results were not materially different in sensitivity analyses restricted
to parous women (data not shown). We observed limited heteroge-
neity in associations by age at blood collection (<60 vs ≥60 years;
Table S5). In the analysis considering “high” and “low” positive anti-
body levels to C. trachomatis cHSP60-1 antibodies and EOC risk,
women with high positive antibody levels had higher risk of EOC
only among women <60 at blood collection (Phet = 0.04; <60 years,
1.91 [1.31-2.78]; ≥60 years, RR: 0.89 [0.49-1.62]). Significant het-
erogeneity by age at blood collection was also observed for the asso-
ciation between HSV-2 and EOC risk (Phet = 0.01; <60 years, 0.59
[0.48-1.00]; ≥60 years, 1.51 [0.97-2.34]). No heterogeneity in asso-
ciations was observed by lag time (<5 years, ≥5 years) or OC use
(ever, never; data not shown); however a borderline significant asso-
ciation between positive Pgp3 serology and EOC risk was observed in
women diagnosed within 5 years of blood collection (1.32 [0.97-1.80]),
but not in women diagnosed ≥5 years from blood collection (0.90
[0.69-1.16]; Phet = .06). No significant heterogeneity in associations was
observed by menopausal status at blood collection (premenopausal, peri-
menopausal, postmenopausal; Phet > .19); however, a statistically signifi-
cant positive association between cHSP60-1 and EOC risk was only
observed among women postmenopausal at blood collection (2.05
[1.15-3.64]).
4 | DISCUSSION
Individual C. trachomatis antibodies were associated with higher risk
of EOC, in particular, cHSP60 antibodies were associated with EOC
overall and the serous subtype, while Pgp3 was associated with the
mucinous subtype, in this large, prospective study. Furthermore, we
observed an association between HSV-2 and the endometrioid EOC
subtype. M. genitalium and HPV showed generally null associations
with EOC risk, and we observed no associations between the investi-
gated STIs and HGSC.
Our findings of positive associations between select
C. trachomatis antibodies and EOC risk are in line with the results of
three previous studies18,19,25; however, others have observed no
association.20,22,24 Previous studies have predominantly analyzed
ovarian cancer as a single disease, with small sample size precluding
analyses by subtype beyond serous vs nonserous dis-
ease.18-20,22,24,25 In the current study, we provide a detailed investi-
gation by histotype, observing suggestive heterogeneity by tumor
histology. Pgp3 serology indicating current or past infection with
C. trachomatis was not associated with EOC risk overall in contrast
to two recent studies,18,25 but was associated with significantly
higher risk of mucinous EOC; this has not previously been described.
This result was robust to statistical adjustment for smoking, in addi-
tion to OC use and parity; however, the number of mucinous ovarian
cancer cases was limited (n = 58) and this result should be inter-
preted with caution.
Positive serology for cHSP60-1 antibodies was associated with
higher risk of EOC overall, and serous disease, as were relatively high
levels of the MOMP-A, MOMP-D and MOMP-L2 antibodies.
cHSP60-1 IgG antibodies were associated with Type II EOC in a sub-
group analysis in a previous study,22 and cHSP60-1 antibodies were
associated with EOC using higher cut-off levels in a retrospective case-
control, but not the prospective component of the study by Trabert
et al.18 Chlamydial HSP60 is produced by the chlamydia bacteria to
induce a persistent state of infection in the host cell, thereby escaping
immune defense.36 This leads to inhibited cell apoptosis increasing the
risk for a DNA-damaged cell to survive, and being further exposed to
an inflammatory environment with cytotoxic substances. This state of
persistent chlamydia infection with increased cHSP60 production is
one pathogenic mechanism by which chlamydia could cause ovarian
cancer.37 Given that cHSP60 is associated with persistent chlamydia
infection, cHSP60-1 antibodies may be a marker of persistent
cHSP60-producing C. trachomatis infection, thus positive serology for
cHSP60-1 antibodies might show an association with ovarian cancer
even in the absence of an association with Pgp3 antibodies, a more
general marker of infection. The explanation for differences in associa-
tions observed between the European population in the current study
and the two prospective studies in U.S.-based populations is not imme-
diately evident. One explanation may be regional differences in
C. trachomatis strains,38 with different strains possibly having different
downstream impacts on the genital tract epithelium; studies character-
izing the impact of different strains of C. trachomatis on the genital tract
are required to clarify potential differing sequelae by strain. Further, dif-
ferences in patterns of seeking healthcare, and differences in screening,
detection and treatment of STIs, may account for the differences in
associations in the study populations.
M. genitalium is a small intracellular bacterium known to cause
PID. Serum antibodies to M. genitalium were not associated with EOC
overall or any histotypes in our study, in line with the findings of pro-
spective studies,18,22 although an association was reported in a retro-
spective case-control study population18 and parous women in
another study.25
Positive HSV-2 serostatus was associated with a higher risk of
endometrioid EOC. A higher, but not statistically significant, risk of EOC
overall was also found in the recent study by Trabert et al.18 Women
with positive serology for HSV-2 had higher risk of endometrial (uterine)
cancer in the NHANES (National Health and Nutrition Examination Sur-
vey).15 Ovarian cancer of the endometrioid subtype shares several char-
acteristics with endometrial cancer and is synchronous with
endometrioid cancer of the uterus in 15%-20% of cases.39 Similar to
previous studies that found no association of HPV serostatus with ovar-
ian cancer,18,25,26,38 no associations were observed in our study.
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The hypothesis that HGSC would be the ovarian cancer subgroup
most likely associated with STI serum markers was not supported by
the results of our study, though these analyses were limited by the
availability of data on grade (available for 59% of all cases, 66% of
serous cases) and, thus, a limited number of HGSC cases (n = 268).
One explanation for the lack of association observed may have been
due to limited power to detect an association in this subgroup. A pos-
sible biologic interpretation is that the secretory cells of the distal
fallopian tube might not be vulnerable to neoplastic transformation
caused by infectious agents, even though one recent study suggests
that C. trachomatis has long-term impact on the tubal epithelium by
altering the phenotype and inducing heritable changes in the
epigenome.40 Only one prospective seroepidemiological study has
analyzed the association of STI antibodies and Type II EOC finding a
significant association of C. trachomatis antibodies with Type II.22
Another explanation could be that analyses of serum antibodies do
not reflect the previous infections that are crucial in malignant trans-
formation of the secretory cells.
Our study has several strengths. First, the present study included the
largest number of cases among seroepidemiological studies focusing on
STI antibodies and risk of EOC published to date, allowing a more detailed
evaluation by histological subtypes and grade than previous studies. Sec-
ond, the prospective design excluded disease-related effects on serologic
antibody levels; however, no data are available on the timing of infection
prior to the blood collection, nor infections in the interval between blood
collection and diagnosis/selection as a control. Third, a validated multiplex
Luminex assay allows us to evaluate antibodies to several candidate STIs
in the study. Seroconversion appears to occur in relatively close temporal
proximity to diagnosis, with a total of 92% of womenwith a positive Pgp3
serology at chlamydia diagnosis and ≥1 day to 6 months after diagnosis,
and positive serology was observed in 72% of individuals >4 years after
diagnosis in one study.41 Wills et al42 reported the sensitivity of a Pgp3
ELISA at 73.8% amongwomenwith known prior chlamydia diagnoses and
≥96% specificity. The Pgp3 assay used in the current study has excellent
agreement with ELISA (kappa ≥ 94%18). A limitation of our study, despite
the large number of cases overall, is that only about two-thirds of serous
cases had histological grade, which limited the analyses of the HGSC sub-
group. Case numbers in other subgroups were limited as well. The ana-
lyses were adjusted for the known risk (or protective) factors parity and
OC use. Other known risk factors not adjusted for due to lack or limita-
tions of available data included hysterectomy, tubal ligation, endometriosis
and family history of ovarian cancer; thus, residual confounding cannot
fully be excluded. However, adjustment for family history of ovarian
and/or breast cancer had minimal impact on effect estimates in the
NHS/NHSII study, and restriction to participants without tubal ligation in
that study resulted in findings similar to the overall results.25Many statisti-
cal tests are reported; therefore, some significant associations may be due
to chance and the results have to be interpretedwith caution.
In conclusion, our study supports a possible role of C. trachomatis and
HSV-2 in ovarian carcinogenesis. History of STIs might be of importance
in the etiology of serous, mucinous and endometrioid ovarian cancer. The
results of our study need to be confirmed in other prospective cohorts of
sufficient size to investigate STIs and risk by tumor histotype.
Experimental studies delineating the mechanisms linking STIs to EOC, and
the primary prevention potential of STI prevention, are tasks for future
experimental, translational and epidemiological research to resolve.
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